tiprankstipranks
Advertisement
Advertisement

HK:1952 Stock Latest News

Everest Medicines Publishes Unaudited Interim Results for First Half of 2026
Company AnnouncementsEverest Medicines Publishes Unaudited Interim Results for First Half of 2026
8d ago
1952
Everest Medicines Sets Out Board Structure and Key Governance Committees
PremiumCompany Announcements
Everest Medicines Sets Out Board Structure and Key Governance Committees
13d ago
1952
Everest Medicines Reshapes Board With Director Resignation and New Appointment
PremiumCompany Announcements
Everest Medicines Reshapes Board With Director Resignation and New Appointment
13d ago
1952
Everest Medicines Sets Board Meeting to Approve 2026 Interim Results
PremiumCompany Announcements
Everest Medicines Sets Board Meeting to Approve 2026 Interim Results
22d ago
1952
Everest Medicines Grants New Options and Share Awards Under 2026 Scheme
PremiumCompany Announcements
Everest Medicines Grants New Options and Share Awards Under 2026 Scheme
1M ago
1952
Everest Medicines Closes High-Value BTK Inhibitor Deal With Travere
PremiumCompany AnnouncementsEverest Medicines Closes High-Value BTK Inhibitor Deal With Travere
2M ago
1952
Everest Medicines Wins Shareholder Backing for All AGM Resolutions
Premium
Company Announcements
Everest Medicines Wins Shareholder Backing for All AGM Resolutions
2M ago
1952
Everest Medicines to Commercialize Hainan Herui’s Budesonide Capsules in Mainland China
Premium
Company Announcements
Everest Medicines to Commercialize Hainan Herui’s Budesonide Capsules in Mainland China
2M ago
1952
Everest Medicines’ Major Shareholder Boosts Stake, Signaling Confidence in Long-Term Outlook
PremiumCompany Announcements
Everest Medicines’ Major Shareholder Boosts Stake, Signaling Confidence in Long-Term Outlook
2M ago
1952
Everest Medicines Shareholders Approve Key Share Purchase Agreement
PremiumCompany Announcements
Everest Medicines Shareholders Approve Key Share Purchase Agreement
2M ago
1952
Everest Medicines Takes Exclusive Asia Rights to Dimerix Kidney Drug DMX-200
PremiumCompany Announcements
Everest Medicines Takes Exclusive Asia Rights to Dimerix Kidney Drug DMX-200
2M ago
1952
Everest Medicines Substantial Shareholder CBC Group Raises Stake
PremiumCompany Announcements
Everest Medicines Substantial Shareholder CBC Group Raises Stake
3M ago
1952
Everest Medicines Secures Greater China Rights to Presbyopia Eye Drop LNZ100
PremiumCompany AnnouncementsEverest Medicines Secures Greater China Rights to Presbyopia Eye Drop LNZ100
3M ago
1952
Everest Medicines Gains Vote of Confidence as Major Shareholder Boosts Stake
Premium
Company Announcements
Everest Medicines Gains Vote of Confidence as Major Shareholder Boosts Stake
3M ago
1952
Everest Medicines Sets 2026 Virtual AGM, Seeks Fresh Share Repurchase and Issuance Mandates
Premium
Company Announcements
Everest Medicines Sets 2026 Virtual AGM, Seeks Fresh Share Repurchase and Issuance Mandates
3M ago
1952
Everest Medicines Calls Virtual EGM to Approve Share Purchase Deal
PremiumCompany Announcements
Everest Medicines Calls Virtual EGM to Approve Share Purchase Deal
3M ago
1952
Everest Medicines Out-Licenses Kidney Drug Civorebrutinib to Travere in Deal Worth Up to US$1.14 Billion
PremiumCompany Announcements
Everest Medicines Out-Licenses Kidney Drug Civorebrutinib to Travere in Deal Worth Up to US$1.14 Billion
3M ago
1952
Everest Medicines Sets EGM Timetable and Delays Acquisition Circular
PremiumCompany Announcements
Everest Medicines Sets EGM Timetable and Delays Acquisition Circular
3M ago
1952
Everest Medicines’ Major Shareholder Lifts Stake in Confidence Boost
PremiumCompany Announcements
Everest Medicines’ Major Shareholder Lifts Stake in Confidence Boost
3M ago
1952
Everest Medicines Director and Major Shareholder Raises Stake in Company
PremiumCompany AnnouncementsEverest Medicines Director and Major Shareholder Raises Stake in Company
3M ago
1952
Everest Medicines Details PSVT Asset Purchase and Readies for China Launch
Premium
Company Announcements
Everest Medicines Details PSVT Asset Purchase and Readies for China Launch
4M ago
1952
Everest Medicines to Buy Asia-Pacific Chronic Disease Portfolio in US$250 Million Deal
Premium
Company Announcements
Everest Medicines to Buy Asia-Pacific Chronic Disease Portfolio in US$250 Million Deal
5M ago
1952

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >